| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.49 | 1e-43 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.46 | 3e-38 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.48 | 3e-38 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.45 | 4e-37 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.43 | 8e-33 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.5 | 4e-23 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.32 | 2e-21 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.45 | 2e-18 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.27 | 6e-18 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.45 | 6e-17 |